Cargando…
Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624465/ https://www.ncbi.nlm.nih.gov/pubmed/37928626 http://dx.doi.org/10.1097/HS9.0000000000000968 |
| _version_ | 1785130931089047552 |
|---|---|
| author | Janssen, Luca L.G. Westers, Theresia M. Rovers, Jeroen Valk, Peter J.M. Cloos, Jacqueline de Gruijl, Tanja D. van de Loosdrecht, Arjan A. |
| author_facet | Janssen, Luca L.G. Westers, Theresia M. Rovers, Jeroen Valk, Peter J.M. Cloos, Jacqueline de Gruijl, Tanja D. van de Loosdrecht, Arjan A. |
| author_sort | Janssen, Luca L.G. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10624465 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106244652023-11-04 Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001 Janssen, Luca L.G. Westers, Theresia M. Rovers, Jeroen Valk, Peter J.M. Cloos, Jacqueline de Gruijl, Tanja D. van de Loosdrecht, Arjan A. Hemasphere Letter Lippincott Williams & Wilkins 2023-11-02 /pmc/articles/PMC10624465/ /pubmed/37928626 http://dx.doi.org/10.1097/HS9.0000000000000968 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Letter Janssen, Luca L.G. Westers, Theresia M. Rovers, Jeroen Valk, Peter J.M. Cloos, Jacqueline de Gruijl, Tanja D. van de Loosdrecht, Arjan A. Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001 |
| title | Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001 |
| title_full | Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001 |
| title_fullStr | Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001 |
| title_full_unstemmed | Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001 |
| title_short | Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001 |
| title_sort | durable responses and survival in high-risk myelodysplastic syndrome and acute myeloid leukemia patients receiving the allogeneic leukemia-derived dendritic cell vaccine dcp-001 |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624465/ https://www.ncbi.nlm.nih.gov/pubmed/37928626 http://dx.doi.org/10.1097/HS9.0000000000000968 |
| work_keys_str_mv | AT janssenlucalg durableresponsesandsurvivalinhighriskmyelodysplasticsyndromeandacutemyeloidleukemiapatientsreceivingtheallogeneicleukemiaderiveddendriticcellvaccinedcp001 AT westerstheresiam durableresponsesandsurvivalinhighriskmyelodysplasticsyndromeandacutemyeloidleukemiapatientsreceivingtheallogeneicleukemiaderiveddendriticcellvaccinedcp001 AT roversjeroen durableresponsesandsurvivalinhighriskmyelodysplasticsyndromeandacutemyeloidleukemiapatientsreceivingtheallogeneicleukemiaderiveddendriticcellvaccinedcp001 AT valkpeterjm durableresponsesandsurvivalinhighriskmyelodysplasticsyndromeandacutemyeloidleukemiapatientsreceivingtheallogeneicleukemiaderiveddendriticcellvaccinedcp001 AT cloosjacqueline durableresponsesandsurvivalinhighriskmyelodysplasticsyndromeandacutemyeloidleukemiapatientsreceivingtheallogeneicleukemiaderiveddendriticcellvaccinedcp001 AT degruijltanjad durableresponsesandsurvivalinhighriskmyelodysplasticsyndromeandacutemyeloidleukemiapatientsreceivingtheallogeneicleukemiaderiveddendriticcellvaccinedcp001 AT vandeloosdrechtarjana durableresponsesandsurvivalinhighriskmyelodysplasticsyndromeandacutemyeloidleukemiapatientsreceivingtheallogeneicleukemiaderiveddendriticcellvaccinedcp001 |